Ampsource Biopharma Shanghai Inc.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Yuncheng Zheng

Qiang Li

Si Ruo Chen

Xinlu Ma

Yuanli Li

Yongjuan Gao

Lu Yang

Zhu Wang

Tongtong Xue

Liang Xiao

Dengnian Liu

Naichao Sun

Zirui Li

Zhao Dong

Jingyi Wang

Lichun Wang

Bill Nai-Chau Sun

Cecily Rou-Yun Sun

Jiangjiang Hu

Yan Hu

Jianyu Sun

Kangyong Zhu

Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Antibody against TIM-3 and application thereof

A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin &#x3b2;-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable.

Linker peptide for constructing fusion protein

The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune response, or are used for preventing and/or treating tumors, infections or autoimmune diseases.

Anti-LAG-3 antibody and use thereof

The invention provides an antibody and/or an antigen binding fragment that binds to NGF, and the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody and/or its antigen binding fragment provided by the invention has high affinity for NGF and can effectively block the binding between NGF receptor and NGF. This antibody and/or its antigen binding fragment can inhibit the binding activity of NGF and its receptor in vitro, and is suitable for the treatment of pain diseases which are related to the haughty expression or increased expression of NGF.

Anti-human NGF antibodies and methods using same

This disclosure provides an antibody specifically binding to PD-1 with high affinity. Also provided are a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method for the antibody. In addition, also provided are an immunoconjugate and a pharmaceutical composition comprising the antibody and use of the antibody in preparation of drugs for treating cancers, infectious diseases, and inflammatory diseases.

Anti-PD-1 antibody and use thereof

Growing community of inventors

Shanghai, China

Yuncheng Zheng